Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) have earned an average recommendation of “Hold” from the nine analysts that are presently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company.

A number of research firms have recently commented on ZLDPF. Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research report on Thursday, June 4th. Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Finally, Jefferies Financial Group cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th.

Get Zealand Pharma A/S alerts:

Read Our Latest Report on ZLDPF

Zealand Pharma A/S Price Performance

Shares of OTCMKTS:ZLDPF opened at $51.80 on Thursday. The company has a 50 day moving average of $45.56 and a 200 day moving average of $49.57. The stock has a market cap of $3.71 billion, a P/E ratio of 3.84 and a beta of 0.88. Zealand Pharma A/S has a 12 month low of $35.93 and a 12 month high of $83.12. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02.

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.

Featured Stories

• Five stocks we like better than Zealand Pharma A/S
• GE Vernova’s AI Power Boom Faces a Profit Test
• Cardinal Health Earnings: Can Perfection Get Priced In Twice?
• Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
• Legacy Jet Builders Stall While Embraer Accelerates to New Highs

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.